chronic immune thrombocytopenic purpura

chronic immune thrombocytopenic purpura

References in periodicals archive ?
The European Commission has approved Switzerland-based Novartis' Revolade for the treatment of children with paediatric chronic immune thrombocytopenic purpura (ITP), it was reported on Friday.
sup][8],[27],[28],[29] An association between chronic immune thrombocytopenic purpura and HCV has been described previously; [sup][27] cryoglubulins, [sup][28] and anti-PLT autoantibodies [sup][29] have been detected in thrombocytopenic patients with HCV.
Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment.
The condition, which usually develops in adults, is known as chronic immune thrombocytopenic purpura (ITP), a disease that results in a low number of platelets, the blood components that help with clotting.
has announced that the FDA has approved Nplate(TM) (romiplostim), the first and only platelet producer for the treatment of thrombocytopenia in splenectomized (spleen removed) and non-splenectomized adults with chronic immune thrombocytopenic purpura (ITP).
Food and Drug Administration (FDA) granted CSL Behring approval to market Privigen, an intravenous immunoglobulin (IGIV), for treating patients diagnosed with primary immunodeficiency (PI) and chronic immune thrombocytopenic purpura (ITP).
Biotechnology company Rigel Pharmaceuticals (NasdaqGS:RIGL) revealed on Tuesday that it has received US Food and Drug Administration (FDA) orphan drug designation for Fostamatinib for treating chronic immune thrombocytopenic purpura (ITP).
NASDAQ:AMGN) today announced results from a randomized, pivotal Phase 3 study that showed romiplostim (AMG 531) increased and sustained platelet counts in splenectomized (spleen removed) adult patients with chronic Immune Thrombocytopenic Purpura (ITP).
Results from six studies evaluating Nplate in adult patients with chronic immune thrombocytopenic purpura (ITP) add to the growing body of data supporting the use of Nplate in this setting, including the final efficacy and safety results from the largest and longest study of Nplate in adult chronic ITP.
Food and Drug Administration (FDA) granted marketing approval to CSL Behring for Privigen, an intravenous immunoglobulin (IVIg), for treating patients diagnosed with primary immunodeficiency (PI) and chronic immune thrombocytopenic purpura (ITP).
Full browser ?